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COMMENTARY
Abstract: Atherosclerotic cardiovascular diseases (CVDs) are the leading cause of death
and disability in the United States. While multiple studies have demonstrated that modification
of atherosclerotic cardiovascular risk factors (CVRFs) significantly reduces morbidity and
mortality rates, clinical control of CVDs and CVRFs remains poor. By 2010, the American
Heart Association seeks to reduce coronary heart disease, stroke, and risk by 25%. To meet
this goal, clinical practitioners must establish new treatment paradigms for CVDs and CVRFs.
This paper discusses one such treatment model – a comprehensive atherosclerosis program
run by physician extenders (under physician supervision), which incorporates evidence-based
CVD and CVRF interventions to achieve treatment goals.
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Atherosclerosis: the failure to achieve
treatment goals
Atherosclerotic cardiovascular diseases (CVDs) have, for decades, been the leading
cause of death and disability in men and women in the United States (AHA 2005a).
There is convincing evidence that treating atherosclerotic cardiovascular
risk factors (CVRFs) (eg, elevated levels of low-density lipoprotein cholesterol
[LDL-C], high blood pressure [BP], and smoking) reduces cardiovascular morbidity
and mortality. This is consistent across a broad range of patients, including those
with particular medical conditions (coronary artery disease [CAD], diabetes, and
hypertension) and those from particular demographic groups (smokers, non-smokers,
women, and the elderly) (Galen 1988; Rosenburg 1990; 4S Study Group 1994;
Shepherd 1995; Voors 1996; Downs 1998; van Erkel 1999; Neal 2000; Collins 2002;
Sever 2003). As a result of these findings, professional societies and organizations
have established standards of practice and treatment goals that are tailored to address
CVDs and CVRFs in different populations. For example, the American Diabetes
Association has established the following recommendations for treating patients with
diabetes, which is now considered a CAD-risk equivalent (Table 1) (Haffner et al
1998; NCEP ATP III 2001; ADA 2003; Gibbons et al 2003).
While meeting these treatment goals has proven effective in combating CAD, a
review of the current literature reveals that in clinical practice only a small
percentage of patients actually achieve the recommended treatment goals. Indeed,
just 18%–25% of adult patients with CAD and/or heart failure met the National
Cholesterol Education Program (NCEP) goal for LDL-C (Sueta et al 1999; Pearson
et al 2000). Similarly, among hypertensives, BP was adequately controlled in
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and Kochen 2003). A mere 2% of current smokers quit
permanently each year (CDC 2000).
While multiple factors are responsible for the failure to
achieve treatment goals for CVRFs, patient nonadherence
to drug therapy is arguably the most primary. Among the
common causes of nonadherence are: patient misunder-
standing of the condition or treatment; denial of illness due
to lack of symptoms; perception of medication as a symbol
of ill health; lack of patient involvement in the care plan;
and unexpected adverse side effects (Chobanian et al 2003).
Additional barriers to successful drug adherence include
those related to the complexity of care; ie, cost of medication
and lack of financial resources, limited transportation,
difficulty scheduling appointments amid life’s competing
demands, and patient difficulty with polypharmacy or failure
to uptitrate (Phillips et al 2001; Chobanian et al 2003; Foley
et al 2003). Sometimes the likelihood for nonadherence can
be identified by particular patient demographics, enabling
doctors to be vigilant with patients at high risk. For example,
male hypertensive patients aged 65 or older who had not
visited a physician within the preceding 12 months were
most likely to have poor control of hypertension (Hyman
and Pavlik 2001).
How can achievement of
treatment goals be improved?
Improving medication adherence
Behavioral models suggest that the most effective therapy
prescribed by the most careful physician will achieve
treatment goals only if the patient is motivated to take the
prescribed medication and to establish and maintain a
healthy lifestyle (Chobanian et al 2003). Patient motivation
can be encouraged in a number of ways. First, each patient’s
cultural background, belief system, and previous
experiences with the healthcare system uniquely influence
his or her attitude toward the use of medication and must be
taken into consideration by the physician (Betancourt et
al 1999). Tailoring his or her interaction to these
considerations, the physician should demonstrate empathy
and build trust with the patient, creating a positive patient–
physician experience that results in increased patient
motivation (Barrier et al 2003). To specifically promote drug
adherence, physicians should encourage patients to share
any concerns or fears of unexpected or disturbing drug
reactions, and then help to mitigate those fears by expressing
empathy and informing the patient of what to do if those
reactions occur (Chobanian et al 2003).
Motivation also improves if the patient and physician
agree upon achievable treatment goals and specific strategies
and timelines for meeting those goals (NCEP ATP III 2001).
When a patient does not meet a goal, the treatment plan
should be modified according to mutually agreed upon
changes (Balas et al 2000; Boulware et al 2001). Finally,
decision support systems, flow sheets, templates, feedback
reminders, involvement of nurse practitioners, and clinical
pharmacists have also proved to be helpful (Balas et al 2000).
Other strategies for achieving
treatment goals
Fonarow et al (2001) have demonstrated that in patients with
established CAD, initiating
 a program of aspirin, statin, beta-
blocker, and angiotensin-converting enzyme therapy in
conjunction with lifestyle counseling, before hospital
discharge, increased post-discharge use of statins from 10%
to 91%.
 This adherence translates into a significant increase
in the number of patients achieving the LDL-C goal of
≤ 100 mg/dL (from 6% to 58%), and a significant decrease
in the rate of death and nonfatal myocardial infarction (from
14.8% to 7.3%).
Other successful strategies for improving the
achievement of treatment goals include: nurse specialist-
Table 1 Recommended treatment goals for patients with type
2 diabetes mellitus
Clinical indicator of the
vascular risk factor Recommended goal
1 Hemoglobin A1C < 7%
a
2 Low-density lipoprotein < 100 mg/dL (< 2.6 mmol/L)
cholesterol
3 High-density lipoprotein 40 mg/dL (men) (> 1.1 mmol/L)b
(HDL-C) cholesterol
4 Triglycerides < 150 mg/dL (< 1.7 mmol/L)
5 Blood pressure < 130/80 mmHg
6 Aspirin therapy (75–325 mg/day) Adults with diabetes and
macrovascular disease
7 Statins Patients with type 2 diabetes and
other cardiovascular risk factors
(Snow 2004)
8 Microalbuminurea < 30 µg/mg of creatinine
9 Therapeutic lifestyle Increased physical activity and
modifications healthy diet
10 Tobacco smoking Counsel about cessation and
offer therapy
Source: Data adapted from ADA (2003).
a Referenced to a nondiabetic range of 4.0%–6.0% using a Diabetes Control and
Complications Trial-based assay.
b For women, it has been suggested that the HDL goal be increased by 10 mg/dL.Vascular Health and Risk Management 2005:1(2) 103
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led hypertension and dyslipidemia clinics (Allen et al 2002;
New et al 2003); combination of two of more medications
(Black et al 2001; Cushman et al 2002); BP self-
measurement (which is helpful in evaluating “white-coat”
hypertension, diagnosing hypertension, and preventing
potential problems) (AHA 2005b); and smoking cessation
interventions (behavioral and pharmacological) (Burt et al
1974; Pozen et al 1977; Taylor et al 1990; DeBusk et al
1994; Carlsson et al 1997; Dornelas et al 2000; Hopkins et
al 2001; Zhu et al 2002; Hilleman et al 2004) geared toward
CAD patients, which involve a high number of contacts and
are of prolonged duration.
A new paradigm for the treatment
of CVRFs and CVDs
To address America’s failure to clinically replicate the
successes of multiple randomized studies – to bring the
successes of these studies from the research bench to the
bedside – the American Heart Association has established
the ambitious goal to reduce coronary heart disease, stroke,
and risk by 25% over current levels by 2010 (Smaha 2000).
If we are to meet this goal, the focus of treatment of CVDs
must change from treating the symptoms of target organs
(such as CAD, stroke, peripheral arterial disease) to the
comprehensive treatment of the underlying disease process
of atherosclerosis.
Since atherosclerosis is caused by multiple modifiable
(ie, preventable) risk factors, it follows that practitioners in
primary care clinics – those on the “front lines” of preventive
care – should be the leaders in this new approach. There is
an urgent need to design, test, and implement evidence-based
programs in outpatient primary care settings devoted to the
primary and secondary prevention of atherosclerosis. The
authors have recently launched such a program – The
Prevention of Heart Attack and Stroke in the Elderly
(PHASE) Clinic – and are currently conducting a 6-month
long feasibility trial to measure its performance against usual
care.
The design of the PHASE Clinic
Designed explicitly for the comprehensive modification of
CVDs and CVRFs, the PHASE Clinic is a half-day weekly
program embedded within a primary care practice of
physicians. The clinic is run jointly by a physician extender
(physician assistant or nurse practitioner) and a supervising
physician. The clinic treats adult and elderly patients (ie,
≥ 50 years) with CVDs and CVRFs, such as established
atherosclerosis of any artery, diabetes, obesity, the metabolic
syndrome, dyslipidemia, hypertension, or smoking. Patients
are initially seen by the physician, with subsequent visits
scheduled with the physician extender. Patients are
scheduled every 30 minutes.
PHASE interventions
1. Lifestyle modification. The clinic provides focused
counseling regarding lifestyle modification, including
weight loss, heart protective dietary choices, adoption
of physical activity, and smoking cessation. We follow
NCEP adult treatment panel III (NCEP ATP III 2001)
recommendations, and utilize techniques from the
“transtheoretical or stages of change” model for
counseling (Greene et al 1999; Sarkin et al 2001;
Anderson et al 2002) (see Appendix A).
2. Patient’s commitment and education materials. At the
end of lifestyle counseling, the patient and healthcare
provider set achievable goals for each identified risk or
disease, which are itemized on a form (Appendix A) that
serves as both a motivational “contract” and an edu-
cational tool. Patients are asked to make a commitment
to the program by initialing the counseling form, which
is then initialed by the healthcare provider. Patients
receive a copy of this double-sided form, which in
addition to the patient’s individualized goals, also
includes educational information about weight loss, heart
protective dietary choices, adoption of physical activity,
and smoking cessation. Patients are advised to refer to
it frequently, follow its instructions, and bring it to the
next visit.
3. Frequent uptitration and/or use of alternative
pharmacotherapy. The clinic employs pharmacotherapy
for atherosclerotic coronary artery disease, carotid artery
atherosclerosis, peripheral artery atherosclerosis,
diabetes, obesity, the metabolic syndrome, dyslipidemia,
hypertension, and smoking cessation. If condition-
specific medications are tolerated by the patient, we
frequently uptitrate; when a particular treatment is not
tolerated, we employ alternative medications.
4. Minimizing polypharmacy. Polypharmacy is minimized
by following Beers Criteria for potentially inappropriate
medication use in older adults (Fick et al 2003).
5. Improving medication adherence. Clinic health providers
utilize proven strategies to promote patient motivation
and improve medication adherence, including
demonstrating empathy, building trust, and cultivatingVascular Health and Risk Management 2005:1(2) 104
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a positive experience during clinic visits (Barrier et al
2003). When considering specific treatment regimens,
practitioners take into account patients’ cultural and
religious beliefs and previous experiences with the
healthcare system (Betancourt et al 1999). Similarly,
practitioners individually tailor each treatment regimen
and timeline, taking into account each patient’s readiness
for change (Boulware et al 2001). Moreover, when a
patient does not meet a CVRF’s recommended goal,
treatment plan changes are only implemented after active
negotiations with the patient. Other strategies employed
to facilitate treatment adherence include use of practice
guidelines (from the American Heart Association/
American College of Cardiology, NCEP ATP III, and
American Diabetic Association), flow sheets, templates,
and confidential feedback postcard reminders about
laboratory or imaging results (Balas et al 2000).
6. Addressing socioeconomic challenges. When patients
face financial and other burdens that prevent their
successful adherence to the program (eg, inability to
purchase medications, difficulty in scheduling
appointments, limited transportation), the clinic refers
them to social services with support mechanisms that
mitigate these needs.
7. Monitoring home-based treatment. Patients are asked
to monitor their disease status at home by recording
blood sugar, BP, pulse and weight; wearing a pedometer;
keeping food and activity diaries; and bringing these
records for review to each clinic visit. Patients with
impairment in daily living activities and/or cognitive
deficits are referred to home health or state-sponsored
programs (that provide nursing home-level care at
patients’ residences) for monitoring and medication
compliance.
8. Referral to specialists. As clinically indicated,
practitioners refer patients to specialists such as
dieticians, nutritionists, psychologists, diabetologists,
and cardiologists.
9. Close follow-up. Patients are closely followed up in the
clinic a minimum of once every three months and more
frequently if necessary.
Outcome measures of the PHASE
Clinic
The outcome measures of the PHASE Clinic include change
in patient’s body weight, BMI, waist circumference, BP,
triglycerides, total cholesterol, LDL-C, HDL-C, hemoglobin
A1C, urine microalbumin, and compliance rate with yearly
diabetic retinal examination, diabetic foot examination at
every visit, use of aspirin, beta-blockers, angiotensin-
converting enzyme inhibitors, and statins, and diet, physical
activity, and smoking cessation counseling, as indicated and
individualized for patients. The PHASE Clinic (with 100
patients) is the unit of randomization, and its outcome
measures will be compared with those of usual primary care
clinic (with 100 patients) providing similar services to adult
and elderly patients.
Financing for the PHASE Clinic
The medically necessary services provided in the PHASE
Clinic are reimbursed through Medicare and other insurance.
Conclusion
Atherosclerosis is a potentially preventable multifactorial
disease. Current literature reveals that most patients with
established CVDs or CVRFs are failing to achieve their
treatment goals. A dedicated, comprehensive atherosclerosis
outpatient program run by a physician extender and
supervising physician is a potentially successful model for
improvement of treatment goals of CVRFs. As outcomes
for the PHASE Clinic feasibility study become available,
the authors will publish these findings so that other clinicians
may replicate the model’s anticipated successes.
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Appendix A
An example of a nutrition, physical activity, and smoking cessation counseling and patient education handout.
continued overleaf
NuActive Lifestyle ©
Nutrition, Activity, and Smoking Cessation 
Prevent Heart Attack, Stroke, and Early Death 
1. OVERWEIGHT OR OBESITY
Are you overweight or obese?  
Healthy weight = healthy Body Mass Index or BMI (body weight divided by square of height) = 18.5 to 24.9 
Overweight means a BMI  25. Obesity means a BMI  30. Current BMI………… Current weight …………  
Health Risks of Obesity or Overweight: Heart attack, stroke, high blood pressure, diabetes, osteoarthritis, lung 
problems, and premature death. These health risks can be reversed or improved by achieving a healthy weight. 
Do you want to lose weight? Yes___ No___ (Recommended weight loss: 10% of body weight in 6 months. Lose ½ to 1 
lb per week).  
Lose 200 kilo calories (kcal) a day = about 10 pounds in 6 months = about 50 lb in 2 & ½ years. 
If you eat 200 kcal less every day or burn 200 kcal more every day, you will lose 10 pounds in 6 months (182 days): 
200 kcal × 182 days = 36,400 kcal deficit in 6 months. Since 3,500 kcal = 1 lb of body fat (Whitney and Rolfes 1996). 
Therefore, 36,400 kcal = 10.4 Lb of wt loss in 6 months = about 50 Lb in 2 & ½ years 
Cut 200 kcal from your day, for example about 20 French fries, 4 Oreo cookies, 16-ounce Coca-Cola, 40 peanuts.
How Much Should We Eat? Eat smaller portions (size of the palm of your hand for meat). Read the labels to find out 
portion size. Start low, go slow. 
Adjusted total daily calorie need to induce weight loss, maintain desirable weight or prevent weight gain =___________ 
Goal:………………………………………………………………………………………………………………………………………. 
2. HEALTHY FOOD CHOICES
What food items did you eat within last 24 hours (McGee et al 1982)? Do you want to adopt healthy eating habits? 
Yes___ No___ 
………………………………………………………………………………………………………………………………………………
  Focus on healthy foods  Examples Vascular Health and Risk Management 2005:1(2) 108
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continued
1 High fiber (20-30 g/d) complex carbohydrates (50-
60%)
Whole grains, legumes/beans, vegetables, nuts, & fruits
2 Replace saturated fats (total fat intake 25-35%) and 
cholesterol with mono- (up to 20% of total fat) & 
poly-unsaturated fats (up to 10% of total fat)
Fish, nuts, olive or canola oils; add plant stanols/ sterols 2 
g/d (eg, Take Control or Benecol) 
3 Proteins (15%)  Soy, beans, nuts, fish & chicken
4 Drink water  8 cups (about half a gallon) daily
5 Eat less: Cholesterol (<200 mg/d), saturated fats (<7% of total calories)  
Avoid: Trans fats, sweets, simple sugar, salt, & high calories.
Goal:………………………………………………………………………………………………………………………………………. 
3. PHYSICAL ACTIVITY
How much weekly physical activity do you do? Do you want to increase your physical activity? Yes___ No___ 
……………………………………………………………………………………………………………………………………………… 
Health Risks of Physical Inactivity: Heart attack, stroke, high blood pressure, diabetes, osteoporosis, gallstones, colon 
cancer, disability, and premature death. These health risks can be improved by regular physical activity. 
Surgeon General’s Recommendation: “30 minutes or more of moderate physical activity on all, or most, days of the 
week.” Example: Brisk walking or gardening for 30 minutes (CDC 1996). Or physical activity to burn 200 kcal per day. 
Walk, Walk, Walk – 10,000 Steps Daily: 10,000 steps = 5 miles = 500 kcal burned. 
Get a Pedometer and count your steps. Try to do 10,000 steps every day. Start low, go slow. 
Goal:………………………………………………………………………………………………………………………………………. 
4. CIGARETTE SMOKING CESSATION: Do you smoke? Yes___ No___ Do you want to quit? Yes___ No___ 
Health risks of smoking 
Smoking increases death from heart attack and stroke 2 times in men and 1.6 times in women aged 65 years and older. 
Smoking also causes lung cancer, COPD (chronic bronchitis and emphysema), impotence, osteoporosis, poor circulation, 
and various other cancers. 
Benefits of quitting smoking 
If you quit smoking, your chances of dying from heart attack and stroke will be reduced to those who had never smoked. 
Additionally, it will also help reduce your chances of getting other health risks associated with smoking, improve your 
quality of life, and save you a substantial amount of money for a comfortable retirement—good health and good life. 
Yes, you can quit smoking. With the help of your health care team you can quit cigarette smoking. Some people quit 
smoking very easily while others might find it difficult to quit. If you have tried in the past and have not been successful,
you are not alone. Most people make repeated quit attempts before they can successfully quit. The key to success is keep 
trying until you quit. Different medicines are available to help you quit smoking. Vascular Health and Risk Management 2005:1(2) 109
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Source: © Muhammad Firdaus, MD, The DW Reynolds Department of Geriatric Medicine, The University of Oklahoma, Oklahoma, USA. Reproduced with permission.
If you are willing to quit smoking (Anderson et al 2002) 
•  Set a quit date 2 weeks from today. 
•  Start cutting down the number of cigarettes you smoke daily. 
•  Ask your family and friends to support you in quitting. 
•  Ask your spouse or friend to quit with you. 
•  Remove all tobacco from your house, vehicle, and work place.  
• Abstain  from  alcohol. 
•  Keep track of triggers of smoking and plan to overcome them. 
•  Join a support group (family, friends, or others); replace your smoking partners with nonsmoking partners. 
•  Replace your cigarette smoking routine with something healthy. 
•  Call our office if you have any problems or concerns. We can help. 
•  Focus on the healthy food choices and regular physical activity to prevent any weight gain. 
•  On the quit date, quit completely. Not even a single puff. 
•  Use nicotine replacement products as directed. 
•  Use smoking cessation prescription medication as directed. 
•  Keep your follow-up appointment in 2 weeks. 
Goal:………………………………………………… My quit date is:………………………………………………………………. 
I make a commitment to a healthy lifestyle. Patient Initials……….…. Date…………….. Physician initials………….